NVDA
NVIDIA
-- 144.470 TSLA
Tesla
-- 410.440 AMD
Advanced Micro Devices
-- 125.370 CRNC
Cerence
-- 19.330 PLTR
Palantir
-- 79.890 
NEWS
Dermata Receives Notice of Allowance for New U.S. Patent for DMT310 for the Treatment of Acne
Tuesday, 10th December at 9:00 am
- This is Dermata's first allowed U.S. patent application for DMT310, using its Spongilla technology to topically treat acne -
- Dermata recently completed enrollment in its DMT310 Phase 3 STAR-1 study for the treatment of acne and expects to announce topline results in March 2025 -
- Over 30 million acne patients seek treatment in the U.S. each year, with topical products being first-line therapy -
Tuesday, 10th December at 9:00 am
- This is Dermata's first allowed U.S. patent application for DMT310, using its Spongilla technology to topically treat acne -
- Dermata recently completed enrollment in its DMT310 Phase 3 STAR-1 study for the treatment of acne and expects to announce topline results in March 2025 -
- Over 30 million acne patients seek treatment in the U.S. each year, with topical products being first-line therapy -
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment